[1]
Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet (London, England). 2004 May 29:363(9423):1802-11
[PubMed PMID: 15172781]
[2]
Wu KL, Sonneveld P. [Thalidomide: new uses for an old drug]. Nederlands tijdschrift voor geneeskunde. 2002 Aug 3:146(31):1438-41
[PubMed PMID: 12190008]
[3]
Annas GJ, Elias S. Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century. American journal of public health. 1999 Jan:89(1):98-101
[PubMed PMID: 9987477]
[4]
Tuinmann G, Hegewisch-Becker S, Hossfeld DK. [New indications for thalidomide?]. Deutsche medizinische Wochenschrift (1946). 2001 Oct 19:126(42):1178-82
[PubMed PMID: 11607859]
[5]
Kumar S, Witzig TE, Rajkumar SV. Thalidomid: current role in the treatment of non-plasma cell malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Jun 15:22(12):2477-88
[PubMed PMID: 15197211]
[6]
Pałgan K, Pałgan I. [Thalidomide--new prospective therapy in oncology]. Wiadomosci lekarskie (Warsaw, Poland : 1960). 2003:56(9-10):455-9
[PubMed PMID: 15049211]
[7]
Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth defects research. Part C, Embryo today : reviews. 2015 Jun:105(2):140-56. doi: 10.1002/bdrc.21096. Epub 2015 Jun 4
[PubMed PMID: 26043938]
[8]
Vargesson N. The teratogenic effects of thalidomide on limbs. The Journal of hand surgery, European volume. 2019 Jan:44(1):88-95. doi: 10.1177/1753193418805249. Epub 2018 Oct 18
[PubMed PMID: 30335598]
[9]
Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL. Clinical pharmacokinetics of thalidomide. Clinical pharmacokinetics. 2004:43(5):311-27
[PubMed PMID: 15080764]
[10]
Pereira BG, Batista LF, de Souza PA, da Silva GR, Andrade SP, Serakides R, da Nova Mussel W, Silva-Cunha A, Fialho SL. Development of thalidomide-loaded biodegradable devices and evaluation of the effect on inhibition of inflammation and angiogenesis after subcutaneous application. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2015 Apr:71():21-8. doi: 10.1016/j.biopha.2015.02.003. Epub 2015 Feb 19
[PubMed PMID: 25960210]
[11]
Eriksson T, Björkman S, Roth B, Höglund P. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. The Journal of pharmacy and pharmacology. 2000 Jul:52(7):807-17
[PubMed PMID: 10933131]
[12]
Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. The AAPS journal. 2005 Mar 22:7(1):E14-9
[PubMed PMID: 16146335]
[13]
Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. Journal of the American Academy of Dermatology. 1996 Dec:35(6):969-79
[PubMed PMID: 8959957]
[14]
Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. The journal of supportive oncology. 2003 Sep-Oct:1(3):194-205
[PubMed PMID: 15334875]
[15]
Brandenburg NA, Bwire R, Freeman J, Houn F, Sheehan P, Zeldis JB. Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention. Drug safety. 2017 Apr:40(4):333-341. doi: 10.1007/s40264-016-0501-2. Epub
[PubMed PMID: 28074423]
[16]
Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood reviews. 2019 Jan:33():24-32. doi: 10.1016/j.blre.2018.06.002. Epub 2018 Jun 21
[PubMed PMID: 30262170]
[17]
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P, IFM 2009 Study. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. The New England journal of medicine. 2017 Apr 6:376(14):1311-1320. doi: 10.1056/NEJMoa1611750. Epub
[PubMed PMID: 28379796]
[18]
Storrar NPF, Mathur A, Johnson PRE, Roddie PH. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens. British journal of haematology. 2019 Apr:185(1):142-144. doi: 10.1111/bjh.15392. Epub 2018 May 22
[PubMed PMID: 29785771]
[19]
Schneider JA, Cohen PR. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Advances in therapy. 2017 Jun:34(6):1235-1244. doi: 10.1007/s12325-017-0530-y. Epub 2017 Apr 24
[PubMed PMID: 28439852]
Level 3 (low-level) evidence
[20]
Stansfield LC, Gonsalves WI, Buadi FK. The use of novel agents in multiple myeloma patients with hepatic impairment. Future oncology (London, England). 2015:11(3):501-10. doi: 10.2217/fon.14.270. Epub
[PubMed PMID: 25675129]
[21]
Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clinical therapeutics. 1999 Feb:21(2):319-30
[PubMed PMID: 10211535]
[22]
Rajkumar SV. Thalidomide in multiple myeloma. Oncology (Williston Park, N.Y.). 2000 Dec:14(12 Suppl 13):11-6
[PubMed PMID: 11204667]
[23]
Singhal S, Mehta J. Thalidomide in cancer: potential uses and limitations. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2001:15(3):163-72
[PubMed PMID: 11437682]
[24]
Reeves S, Pelone F, Harrison R, Goldman J, Zwarenstein M. Interprofessional collaboration to improve professional practice and healthcare outcomes. The Cochrane database of systematic reviews. 2017 Jun 22:6(6):CD000072. doi: 10.1002/14651858.CD000072.pub3. Epub 2017 Jun 22
[PubMed PMID: 28639262]
Level 1 (high-level) evidence
[25]
O'Leary KJ, Johnson JK, Manojlovich M, Goldstein JD, Lee J, Williams MV. Redesigning systems to improve teamwork and quality for hospitalized patients (RESET): study protocol evaluating the effect of mentored implementation to redesign clinical microsystems. BMC health services research. 2019 May 8:19(1):293. doi: 10.1186/s12913-019-4116-z. Epub 2019 May 8
[PubMed PMID: 31068161]
Level 2 (mid-level) evidence